MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes

Fundamental and Clinical Pharmacology

Volumn 17, Issue 4, 2003, Pages 463-469

  Oselin, Kersti ^a,b   Gerloff, Thomas ^a   Mrozikiewicz, Przemyslaw M ^a   Pähkla, Rein ^b   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

MDR1 genetic polymorphism; P glycoprotein; Peripheral blood lymphocytes; Rh123 efflux

Indexed keywords

CD4 ANTIGEN; CD56 ANTIGEN; DNA; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; RIFAMPICIN; VERAPAMIL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TRANSPORT; EXON; FLOW CYTOMETRY; FLUORESCENCE; GENETIC POLYMORPHISM; GENOTYPE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIGENS, CD4; ANTIGENS, CD56; EXONS; GENES, MDR; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTES; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RHODAMINE 123; RIFAMPIN; T-LYMPHOCYTES, HELPER-INDUCER; VERAPAMIL;

EID: 0041592734     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00163.x     Document Type: Article

References (20)

1. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. (1993) 62 385-427.
2. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A.A.M., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. (1995) 96 1698-1705.
3. Sparreboom A., van Asperen J., Mayer U. et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA (1997) 94 2031-2035.
4. Kim R.B., Fromm M.F., Wandel C. et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. (1998) 101 289-294.
5. Dale K.Y. The contribution of P-glycoprotein to pharmacokinetic drug-rug interactions. J. Cin. Pharmacol. (1999) 39 1203-1211.
6. Kim A.E., Dintaman J.M., Waddell D.S., Silverman J.A. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. (1998) 286 1439-1445.
7. Li L.Y., Amidon G.L., Kim J.S. et al. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J. Pharmacol. Exp. Ther. (2002) 301 586-593.
8. Ito S., Woodland C., Harper P.A., Koren G. P-glycoprotein mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. Life Sci. (1993) 53 PL25-PL31.
9. Greiner B., Eichelbaum M., Fritz P. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. (1999) 104 147-153.
10. Mickley L.A., Lee J-S., Weng Z. et al. Genetic polymorphism in MDR1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood (1998) 91 1749-1756.
11. Hoffmeyer S., Burk O., von Richter O. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97 3473-3478.
12. Drescher S., Scaeffeler E., Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. (2002) 53 526-534.
13. Ludescher C., Pall G., Irschick E.U., Gastl, G. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br. J. Haematol. (1998) 101 722-727.
14. Drach D., Zhao S., Drach J. et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood (1992) 80 2729-2734.
15. Robey R., Bakke S., Stein W. et al. Efflux of rhodamine from CD56 cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC833. Blood (1999) 93 306-314.
16. Tanabe M., Ieiri I., Nagata N. et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (mdr)-1 gene. J. Pharmacol. Exp. Ther. (2001) 297 1137-1143.
17. + natural killer cells. Pharmacogenetics (2001) 11 293-298.
18. + hematopoietic stem cells. Haematologica (2002) 87 564-568.
19. Daoud R., Kast C., Gros P., Georges E. Rhodamine 123 binds to multiple sites in the multidrug resistance protein. Biochemistry (2000) 39 15344-15352.
20. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately upregulate these proteins in human colon carcinoma cells. Mol. Pharmacol. (1996) 49 311-318.